甲胎蛋白异质体在肝细胞癌中的诊断价值分析  

Study on Diagnostic Value of AFP-L3 in Hepatocellular Carcinoma

作　　者：张佳斌[1] 纪旭[1] 任辉[1] 孟令展[1] 张晓峰[1] 王洪波[1] 刘振文[1] 

机构地区：[1]解放军302医院肝胆外科二中心,北京100039

出　　处：《现代生物医学进展》2015年第11期2112-2114,共3页Progress in Modern Biomedicine

基　　金：302医院院长创新课题(YNKT2013020)

摘　　要：目的:探讨甲胎蛋白异质体(AFP-L3)的检测对肝细胞肝癌(HCC)的诊断价值。方法:选取2009年2月至2012年11月在本院治疗的90例HCC患者为研究组,另选择同期接受治疗的慢性乙型肝炎患者30例和肝炎肝硬化患者30例作为对照组。观察三组患者的AFP、AFP-L3阳性率。结果:肝癌患者AFP和AFP-L3阳性率显著高于乙肝和肝硬化患者,差异具有统计学意义(P<0.05)。乙肝和肝硬化两组患者的AFP及AFP-L3阳性率无显著差异(P>0.05)。AFP>400 ng/m L:肝癌组AFP-L3阳性率显著高于乙肝组和肝硬化组,差异具有统计学意义(P<0.05)。结论:AFP-L3在HCC中的诊断价值较甲胎蛋白大,更适合在临床诊断中应用。Objective： To explore the diagnostic value of AFP-L3 in hepatocellular carcinoma（HCC）. Methods： 90 HCC patients hospitalized in our hospital from February 2009 to November 2012 were enrolled as research group. 30 cases with chronic hepatitis B and 30 cases with hepatitis liver cirrhosis from the same period were chosen as control group. The positive rates of AFP and AFP-L3 in two groups were observed. Results： The positive rates of AFP and AFP-L3 was 81.1% in research group and 43.3% in control group, and the differences were significant（P0.05）. The positive rate of was 76.7% in research group and 16.7% in control group, and the differences were significant（x2=51.988, P0.05）. Based on the tumor size, the research group was divided into three subgroups（≤5, 5tumor diameter 10, ≥10）. The differences of positive rate of AFP-L3 among three subgroups were not significant（P 0.05）.Conclusion： Compared detection of AFP and AFP-L3 could be better for the diagnosis and prognosis of HCC.

关 键 词：甲胎蛋白异质体 肝细胞癌 恶性肿瘤 诊断价值 

分 类 号：R735.7[医药卫生—肿瘤] R730.45[医药卫生—临床医学]